Skip to main content
AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
201.47
+2.83 (1.42%)
At close: Aug 13, 2025, 4:00 PM
201.50
+0.03 (0.01%)
After-hours: Aug 13, 2025, 7:52 PM EDT

AbbVie Revenue by Segment
Period Ending Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Immunology
28.24B 27.58B 26.68B 26.34B 26.08B 25.92B 26.14B 27.11B
Immunology Growth
8.27% 6.39% 2.09% -2.83% -6.78% -8.64% -9.64% -2.30%
Neuroscience
9.84B 9.32B 9.00B 8.58B 8.26B 7.99B 7.72B 7.33B - - - - - - -
Neuroscience Growth
19.03% 16.64% 16.61% 17.06% 18.70% 18.59% 18.21% 13.30% - - - - - - -
Hematologic Oncology
6.69B 6.65B 6.56B 6.37B 6.20B 6.04B 5.92B 6.04B
Hematologic Oncology Growth
7.89% 9.98% 10.82% 5.57% 0.37% -4.81% -10.07% -11.47%
Aesthetics
4.92B 5.03B 5.18B 5.25B 5.25B 5.24B 5.29B 5.21B - - - - - - -
Aesthetics Growth
-6.31% -4.08% -2.23% 0.75% -0.44% -0.30% -0.73% -4.46% - - - - - - -
Other Products
3.63B 3.56B 3.65B 3.70B 3.79B 3.78B 3.81B 3.82B
Other Products Growth
-4.24% -5.85% -4.15% -3.14% -1.51% -2.50% -1.25% -11.01%
HCV
- - - - - - - - - - - - - - - - - - - - - 2.68B 2.93B 3.16B 3.32B
Eye Care
2.19B 2.21B 2.24B 2.18B 2.26B 2.35B 2.42B 2.42B - - - - - - -
Eye Care Growth
-3.10% -5.76% -7.16% -9.88% -7.26% -7.60% -10.59% -21.20% - - - - - - -
Women's Health
- - - - - - - - - - - - - - 796.00M 829.00M 866.00M 822.00M - - - - - - -

Revenue by Geography
Period Ending Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
United States
44.62B 43.97B 43.03B 42.41B 42.11B 41.72B 41.88B 42.97B
United States Growth
5.97% 5.38% 2.74% -1.30% -4.03% -6.38% -8.38% -4.94%
International
13.71B 13.40B 13.31B 13.13B 12.89B 12.68B 12.44B 12.17B
International Growth
6.31% 5.68% 7.00% 7.85% 6.12% 4.15% 0.76% -3.55%

Operating Expense Breakdown
Period Ending Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018
Selling, General, and Administrative
14.61B 14.73B 14.75B 14.09B 13.26B 13.15B 12.87B 13.10B
Selling, General, and Administrative Growth
10.18% 12.03% 14.61% 7.59% 1.76% -13.34% -15.65% -13.29%
Research and Development
13.10B 12.92B 12.79B 7.94B 7.54B 7.32B 7.68B 7.54B
Research and Development Growth
73.84% 76.44% 66.66% 5.39% 1.45% 0.23% 17.90% 15.14%
Acquired In-Process R&D
2.73B 2.84B 2.76B 1.47B 1.45B 792.00M 778.00M 739.00M - - -
Acquired In-Process R&D Growth
88.20% 258.71% 254.37% 98.24% 103.23% 12.82% 11.62% -13.97% - - -
Other Expenses
-62.00M - -352.00M - - - - - -358.00M -22.00M - - - - - - - - - - -
Other Expenses Growth
- - - - - - - - - - - - - - - - - - - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.